NOVITÀ

As an inhibitory receptor, NKG2A forms a heterodimer with CD94 (KLRD1). In non-target cells, this CD94/NKG2A complex will interact with the non-classical MHC class I molecule HLA-E, inhibiting NK cell and T cell activation via the tyrosine phosphatases SHP-1 or SHP-2 signaling cascades.

Much like other immune checkpoints (for example, PD-1/PD-L1), CD94/NKG2A-HLA-E is leveraged by cancer cells seeking to evade the immune system.

As an activating receptor, NKG2D is a vital anti-tumor signaling axis. It is activated in humans by its ligands, including MICA, MICB, and ULBPs (ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6). This receptor is activated by the H60 (a–c), RAE(α–ε) and MULT1 families in mice.

In mice, NKG2D employs the adaptor molecules DAP10 and DAP12 to help relay its signal transduction. In humans, however, NKG2D has been found to associate exclusively with DAP10. It has a key role to play in fighting against viral infections, and can also regulate cytokine production; for example, IL-10, IL-9, IL-13.

NKG2D/NKG2D ligands

Sino Biological has successfully developed a number of high-activity NKG2D and NKG2D ligands proteins from a number species. These proteins are designed to help researchers study NKG2D/NKG2D ligand biology.

Binding activity validated by ELISA assay

• Ligands bind with NKG2D (Cat#: 10575-H07B)
• Human ULBP1 (Cat#: 10679-H03H)
• Human ULBP6 (Cat#: 15759-H02H)
• NKG2D binds with MICA (Cat#: 12302-H08H)
• Human NKG2D (Cat#: 10575-H01S)
   

NKG2A/NKG2A ligands

NKG2A and NKG2A ligand proteins from a number of species have also been developed, along with a comprehensive panel of antibodies designed to target MICA, MICB, NKG2A, NKG2D, NKG2E, ULBP1 and ULBP2.

Table 1. Source: Sino Biological Inc.

NKG2 related antibodies

These antibodies can be used in ELISA, FCM, WB, IHC, IF and more. A human MICB ELISA kit and ELISA pair set can also be provided on request.

Anti-NKG2A antibodies

Table 2. Source: Sino Biological Inc.

Anti-NKG2D antibodies

Table 3. Source: Sino Biological Inc.